DACH1 mutation frequency in endometrial cancer is associated with high tumor mutation burden.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2020
Historique:
received: 06 10 2020
accepted: 11 12 2020
entrez: 30 12 2020
pubmed: 31 12 2020
medline: 19 3 2021
Statut: epublish

Résumé

DACH1 is a transcriptional repressor and tumor suppressor gene frequently mutated in melanoma, bladder, and prostate cancer. Loss of DACH1 expression is associated with poor prognostic features and reduced overall survival in uterine cancer. In this study, we utilized the Oncology Research Information Exchange Network (ORIEN) Avatar database to determine the frequency of DACH1 mutations in patients with endometrial cancer in our Kentucky population. We obtained clinical and genomic data for 65 patients with endometrial cancer from the Markey Cancer Center (MCC). We examined the clinical attributes of the cancers by DACH1 status by comparing whole-exome sequencing (WES), RNA Sequencing (RNASeq), microsatellite instability (MSI), and tumor mutational burden (TMB). Kentucky women with endometrial cancer had an increased frequency of DACH1 mutations (12/65 patients, 18.5%) compared to The Cancer Genome Atlas (TCGA) endometrial cancer population (25/586 patients, 3.8%) with p-value = 1.04E-05. DACH1 mutations were associated with increased tumor mutation count in both TCGA (median 65 vs. 8972, p-value = 7.35E-09) and our Kentucky population (490 vs. 2160, p-value = 6.0E-04). DACH1 mutated patients have a higher tumor mutation burden compared to DACH1 wild-type (24 vs. 6.02, p-value = 4.29E-05). DACH1 mutations showed significant gene co-occurrence patterns with POLE, MLH1, and PMS2. DACH1 mutations were not associated with an increase in microsatellite instability at MCC (MSI-H) (p-value = 0.1342). DACH1 mutations are prevalent in Kentucky patients with endometrial cancer. These mutations are associated with high tumor mutational burden and co-occur with genome destabilizing gene mutations. These findings suggest DACH1 may be a candidate biomarker for future trials with immunotherapy, particularly in endometrial cancers.

Identifiants

pubmed: 33378353
doi: 10.1371/journal.pone.0244558
pii: PONE-D-20-31424
pmc: PMC7773279
doi:

Substances chimiques

DACH1 protein, human 0
Eye Proteins 0
MLH1 protein, human 0
Poly-ADP-Ribose Binding Proteins 0
Transcription Factors 0
DNA Polymerase II EC 2.7.7.7
POLE protein, human EC 2.7.7.7
PMS2 protein, human EC 3.6.1.-
Mismatch Repair Endonuclease PMS2 EC 3.6.1.3
MutL Protein Homolog 1 EC 3.6.1.3

Types de publication

Comparative Study Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0244558

Subventions

Organisme : NCI NIH HHS
ID : P30 CA177558
Pays : United States

Déclaration de conflit d'intérêts

The employment of Dr. Oliver Hampton by M2GEN does not alter our adherence to PLOS ONE policies on sharing data and materials.

Références

Nucleic Acids Res. 2012 May;40(10):4288-97
pubmed: 22287627
Bioinformatics. 2010 Jan 1;26(1):139-40
pubmed: 19910308
Cancer Biol Ther. 2009 Aug;8(16):1534-9
pubmed: 19502783
Oncogenesis. 2015 Mar 16;4:e143
pubmed: 25775416
Cancer Res. 2009 Jul 15;69(14):5752-60
pubmed: 19605405
Oxid Med Cell Longev. 2019 Jun 2;2019:5084689
pubmed: 31281582
Hum Pathol. 2017 Dec;70:121-128
pubmed: 29107668
Science. 2015 Apr 3;348(6230):124-8
pubmed: 25765070
Mol Cell Biol. 2006 Oct;26(19):7116-29
pubmed: 16980615
Oncotarget. 2017 Jan 31;8(5):7452-7463
pubmed: 27980218
Cancer J. 2011 Nov-Dec;17(6):528-36
pubmed: 22157297
Nat Commun. 2013;4:1635
pubmed: 23535656
Mol Cell Neurosci. 2013 May;54:108-20
pubmed: 23481413
Transl Lung Cancer Res. 2018 Dec;7(6):661-667
pubmed: 30505710
Development. 1994 Dec;120(12):3473-86
pubmed: 7821215
Clin Pharmacol Ther. 2018 Jul;104(1):23-26
pubmed: 29570791
Ann Diagn Pathol. 2017 Oct;30:47-51
pubmed: 28965628
J Clin Oncol. 2017 Aug 1;35(22):2535-2541
pubmed: 28489510
Nature. 2013 May 2;497(7447):67-73
pubmed: 23636398
Bioinformatics. 2014 Apr 1;30(7):1015-6
pubmed: 24371154
PLoS One. 2010 Oct 04;5(10):
pubmed: 20957180

Auteurs

McKayla J Riggs (MJ)

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Kentucky, Lexington, Kentucky, United States of America.

Nan Lin (N)

College of Pharmacy, University of Kentucky, Lexington, Kentucky, United States of America.

Chi Wang (C)

Department of Biostatistics, College of Public Health, University of Kentucky, Lexington, Kentucky, United States of America.
Markey Cancer Center, University of Kentucky, Lexington, Kentucky, United States of America.

Dava W Piecoro (DW)

Division of Pathology, Department of Pathology and Laboratory Medicine, University of Kentucky, Lexington, Kentucky, United States of America.

Rachel W Miller (RW)

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Kentucky, Lexington, Kentucky, United States of America.
Markey Cancer Center, University of Kentucky, Lexington, Kentucky, United States of America.

Oliver A Hampton (OA)

Department of Bioinformatics and Biostatistics, M2Gen, Tampa, Florida, United States of America.

Mahadev Rao (M)

Department of Pharmacy Practice, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, India.

Frederick R Ueland (FR)

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Kentucky, Lexington, Kentucky, United States of America.
Markey Cancer Center, University of Kentucky, Lexington, Kentucky, United States of America.

Jill M Kolesar (JM)

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Kentucky, Lexington, Kentucky, United States of America.
College of Pharmacy, University of Kentucky, Lexington, Kentucky, United States of America.
Markey Cancer Center, University of Kentucky, Lexington, Kentucky, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH